June 21, 2022
Life Sciences
  • fizer agreed to invest $95 million to buy an 8.1 percent percent stake in French vaccines company Valneva. Pfizer and Valneva previously partnered to create a joint Lyme disease program, which is developing a Lyme disease vaccine candidate called VLA15. Valneva is expected to use the investment to support its Phase 3 development study of that vaccine. (Press release here; Article here)